FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

aton, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 2

OMB AF	PPROVAL
OMB Number:	3235-028
H =	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

37 Estimated average burden hours per response: 0.5

								, 00					0. 20.0								
Name and Address of Reporting Person* Marshall Paul						2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ HRTX]										ck all applic	cable)	g Pers	son(s) to Iss 10% Ov Other (s	vner	
(Last) 123 SAG	(F INAW DR	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/05/2015										below)	.0	cal O	below)		
(Street) REDWOOD CITY CA 94063						4. If Amendment, Date of Original Filed (Month/Day/Year)										ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)													. 0.00.	•				
		Tab	le I - Nor	ı-Deriv	vativ	e Se	curit	ies Ac	quir	red, D	Disp	osed o	f, or B	enef	iciall	/ Owned					
Di			Date			2A. Deemed Execution Date, if any (Month/Day/Year)		, T	Code (Instr.						and Securities Beneficially Owned Follo		Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
									С	Code	v	Amount	(A) (D)	or F	Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common	mon Stock 0			03/0	5/2015				ı	M ⁽¹⁾		70,00	0 A		\$9.4	70,	70,000		D		
Common	Stock			03/0	5/201	.5				S ⁽¹⁾		50,00	0 I)	\$14.4	20,	,000	D			
Common	Stock			03/0	5/201	.5				S ⁽¹⁾		20,00	0 I		\$15.4		0	D			
		7	Fable II - I									sed of, onvertil				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (8)				Expi	ate Exe iration I nth/Day	Date		of Secu Underly Derivati	7. Title and Amou of Securities Underlying Derivative Securi Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve es ially ng ed etion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title	or Nu of	nount mber ares						
Stock Option (Right to Buy) ⁽²⁾	\$9.4	03/05/2015			M ⁽¹⁾			70,000		(3)	1	1/01/2023	Commo Stock	70	,000	\$0.00	140,00	00	D		

Explanation of Responses:

- 1. The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of December 16, 2014.
- 2. The option granted on November 1, 2013 was a non-plan grant under an agreement with terms substantially the same as applicable to options granted under the Company's 2007 Equity Incentive Plan.
- 3. Options vested with respect to 52,500 of the underlying shares on November 1, 2014 and pursuant to the terms of the grant, the unvested portion vests pro rata on a monthly basis over the next three years, equaling 4,375 shares per month.

Remarks:

/s/ Brian G. Drazba Attorneyin-fact for Paul Marshall

03/09/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

- I hereby constitute and appoint each of Brian G. Drazba, Esme C. Smith, and Lisa R. Pereza individually as my true and lawful attorney-in-fact to:
- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Heron Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Act"), and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, is intended to benefit, is in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve.

The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any act requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all the acts such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

By: /s/ Paul Marshall Print Name: Paul Marshall

Date: 12/5/2014